|
US2015252371A1
|
|
Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
|
|
AU2014265070A1
|
|
Rna antagonist compounds for the modulation of beta-catenin
|
|
AU2014208214A1
|
|
Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
|
|
GB201408623D0
|
|
Oligomers and oligomer conjugates
|
|
WO2014118272A1
|
|
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
AU2013254923A1
|
|
Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide
|
|
US2014031409A1
|
|
Methods for treating androgen receptor dependent disorders including cancers
|
|
US2014294897A1
|
|
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
|
BR112014021612A2
|
|
compositions and methods for modulating atxn3 expression
|
|
AU2012334045A1
|
|
Compounds for the modulation of SMN2 splicing
|
|
WO2013068348A1
|
|
Lna oligomers for improvement in hepatic function
|
|
WO2012175733A1
|
|
Hcv combination therapy
|
|
WO2013000856A1
|
|
Hcv combination therapy
|
|
WO2013000855A1
|
|
Hcv combination therapy
|
|
WO2012143427A1
|
|
Anti polyomavirus compounds
|
|
WO2012110457A2
|
|
Compounds for the modulation of osteopontin expression
|
|
WO2012066093A1
|
|
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
|
WO2012066092A1
|
|
Compounds for the modulation of aurora kinase a expression
|
|
WO2012034942A1
|
|
Compounds for the modulation of aurora kinase b expression
|
|
WO2012007477A1
|
|
Anti hcv oligomers
|
